In Silico World / Community

In Silico World:
a community
of practice

We believe that one effective way to accelerate adoption of in silico technologies is to establish a pre-competitive safe space where professionals working in academia, industry, regulators agencies, research hospitals, software houses, and contract research organisations can exchange information and establish best practices.

Community of Practice

The adoption of In Silico Trials is a disruptive change and, like all major changes, it encounters some resistance.

To overcome this resistance, we thought of a safe, pre-competitive space where all experts and practitioners from academia, industry and regulatory agencies can ask for advices, exchange information, develop best practices and discuss anything else that can make the use of In Silico Trials an accepted practice.

The community is configured like a forum where members can join teams and collaboratively work on shared goals, projects, concerns, problems or topics.

The community is invitation-only: in this way we assure that only experts with professional interest in in silico medicine have access to the channels and resources.

Our community is open and free to anyone with professional interest in In Silico Medicine, as of January 2022 it sees the participation of 442 experts, including individuals from:

  • Large biomedical companies such as Medtronic, Smith & Nephew, Pfizer, Johnson and Johnson, Innovative Medicine Initiative, CSL Behring, Ambu, RS-Scan, Corwave EN, Zimmer Biomet, Novartis, Bayer, ATOS, Biogen, Agfa, Icon PLC, Amgen, ERT, Exponent, etc.
  • Biomedical SMEs such as Nova Discovery, Lynkeus, Obsidian Biomedical, Quibim, Mediolanum Cardio Research, Voisin Consulting, CRM-Microport, Mimesis srl, H.M. Pharmacon, MCHCE, etc.
  • Independent Software Vendors such as Ansys, In Silico Trials Technologies, 3DS, KIT, ASD Advanced Simulation & Design GmbH, Kuano-AI, Aparito, Chemotargets, Digital Orthopaedics, ExactCure, Materialise, Bio-CFD, Matical, FEOPS, 4RealSim, Exploristics, Synopsis, Virtonomy, Cad-Ferm Medical, etc.
  • Regulators and standardisation bodies such as FDA, DIN, BSCI China, NICE, Critical Path Institute, ACQUAS, etc
  • Clinical research institutions such as Istituto Ortopedico Rizzoli, Sloan Kettering Cancer Center, Royal College of Surgeons Ireland, Gratz University Hospital, Charite Berlin, Centre Nacional Investigaciones Oncologicas, Aspirus Health, Univeritatsklinikum des Saarlandes, European Society for Pediatric Oncology, etc

> JOIN NOW

Initiatives

The practice of In Silico Trials is still far from being established. Most of the research so far has been conducted in academic laboratories and thus far from the needs of industrial users. This is why our community works to consolidate a set of industrial practices that make easier and reliable the development and use of In Silico Trials solutions.

In Silico World is currently supporting several initiatives in this area:

> Good Simulation Practice (GSP)

> Scalability

> #dHealth4Trials

Community
Administrators

As our community keeps growing and recently reached 400 members, we felt the need to establish a small governance that reflects and represents its members.

This is why every channel in the community now has an administrator, who is invited to the private channel @Governance, where all admins will discuss and take decisions for the life of the community.

A

Community Administrators

  • Marco Viceconti, Alma Mater Studiorum – Università di Bologna, as Founder of the community and Admin of #GoodSimulationPractices and #Goals,

 

  • Roberta De Michele, VPH Institute, as Community Manager and Admin of #General and #OffTopic

 

  • Goran Stanic, VPH Institute, as Community Manager and Admin of #General and #OffTopic

 

  • Alfons Hoekstra, University of Amsterdam, as Admin of #ist_solutions

 

  • Angel Alberich, CEO of QUIBIM, as Admin of #Cancer

 

  • Cristina Curreli, Alma Mater Studiorum – Università di Bologna, as Admin of #insilicomedicine_unibo

 

  • David Wifling, Leibniz Supercomputing Centre, as Admin of #CoDesign

 

  • Emily Lumley, University College London, as Admin of #CompBioMed-AHM

 

  • Giorgio Davico, Alma Mater Studiorum – Università di Bologna, as Admin of #dhealth4trials

 

  • Francesco Pappalardo, University of Catania, as Admin of #IST_Research_Projects

 

  • Giulia Russo, University of Catania, as Admin of #Stritvuad_UISS-TB

 

  • Marco Verdicchio, SURF Dutch Supercomputing Centre, as Admin of #CompBioMed-WP4

 

Go to Good Simulation Practice →